brand logo

Am Fam Physician. 2005;72(11):2322-2325

Clinical Question: Are cholinesterase inhibitors effective in patients with Alzheimer’s disease?

Setting: Various (meta-analysis)

Study Design: Meta-analysis (randomized controlled trials)

Synopsis: Three medications for Alzheimer’s disease work by inhibiting cholinesterase: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). The authors of this meta-analysis combined the results of 22 randomized controlled trials evaluating the drugs’ effects on clinical outcomes. The research was identified by searching three databases for studies in any language. Three researchers independently selected studies on the basis of predetermined criteria. Many of the studies were of poor quality; the most common problem was that the results were not analyzed by intention to treat, which can inflate the evidence of benefit. Most studies evaluated patients using the Alzheimer’s Disease Assessment Scale-Cognitive subscale, which uses scores ranging from zero (no impairment) to 70 (very severe impairment). For all three medications, the differences between the treatment and placebo groups were 1.5 to 3.9 points. In 12 trials, effectiveness also was measured using the Clinician’s Interview-Based Impression of Change; the scores were not significantly different between treatment and placebo groups. One study used a measure of cognitive decline and showed an average of five months’ delay with donepezil compared with placebo before a clinically evident functional decline was noted.

Bottom Line: The evidence supporting the effectiveness of cholinesterase inhibitors is based on exceedingly small effects found in poorly analyzed studies. Studies of Alzheimer’s drugs need to be scrutinized carefully for methodologic errors that inflate the appearance of benefit. (Level of Evidence: 1a)

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading


More in AFP

Copyright © 2005 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.